Author's Reply to Trechot: "Comment on Levothyrox^® New and Old Formulations: Are they Switchable for Millions of Patients?"

Affiliations

¹ INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France.
² Service de Pharmacologie Médicale et Clinique, Faculté de Médecine, Centre Hospitalier Universitaire de Toulouse, Université de Toulouse, Toulouse, France.
³ The Royal Veterinary College, University of London, London, UK.
⁴ INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France. pltoutain@wanadoo.fr.
⁵ The Royal Veterinary College, University of London, London, UK. pltoutain@wanadoo.fr.

Comment

Didier Concordet et al. Clin Pharmacokinet. 2019 Jul.

. 2019 Jul;58(7):979-980.

doi: 10.1007/s40262-019-00787-9.

¹ INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France.
² Service de Pharmacologie Médicale et Clinique, Faculté de Médecine, Centre Hospitalier Universitaire de Toulouse, Université de Toulouse, Toulouse, France.
³ The Royal Veterinary College, University of London, London, UK.
⁴ INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France. pltoutain@wanadoo.fr.
⁵ The Royal Veterinary College, University of London, London, UK. pltoutain@wanadoo.fr.

No abstract available

Comment on

Levothyrox^® New and Old Formulations: Are they Switchable for Millions of Patients?
Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran A, Toutain PL. Concordet D, et al. Clin Pharmacokinet. 2019 Jul;58(7):827-833. doi: 10.1007/s40262-019-00747-3. Clin Pharmacokinet. 2019. PMID: 30949873 Free PMC article.
Comment on: Levothyrox^® New and Old Formulations: Are They Switchable for Millions of Patients?
Tréchot P. Tréchot P. Clin Pharmacokinet. 2019 Jul;58(7):977-978. doi: 10.1007/s40262-019-00784-y. Clin Pharmacokinet. 2019. PMID: 31187471 No abstract available.

1. Trechot P. Comment on “Levothyrox^® New and Old Formulations: Are they Switchable for Millions of Patients?”. Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00784-y . - DOI - PubMed
1. Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox^® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00747-3 (epub 4 Apr 2019). - DOI - PubMed - PMC
1. Aronson JK, La Caze A, Kelly MP, Parkkinen V-P, Williamson J. The use of mechanistic evidence in drug approval. J Eval Clin Pract. 2018;24:1166–76. - DOI
1. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265–78. - DOI
1. Chen M-L, Sadrieh N, Yu L. Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugs. AAPS J. 2013;15:1043–50. - DOI